UnitedHealth Group's stock has plunged about 45% YTD, reflecting a series of structural headwinds. Wall Street sentiment is overwhelmingly negative, with analysts forecasting a 30%+ YoY EPS drop over the next three quarters and universally revising Q2 earnings estimates downward. Rising medical utilization and a surge in elective care have driven up costs, eroding profitability and signaling that the pandemic-era tailwinds are firmly in the past.
After a tumultuous first half of the year, American insurance giant UnitedHealth (NYSE: UNH) is back in focus ahead of its Q2 earnings report, scheduled for July 29.
CVS shows resilience with stable insurance margins and capital discipline, while UNH faces cost headwinds and a sharp earnings cut.
UNH braces for a steep Q2 profit drop as soaring medical costs and DOJ scrutiny shake investor confidence.
UnitedHealth Group says it is cooperating with federal criminal and civil investigations involving its market-leading Medicare business.
In the closing of the recent trading day, UnitedHealth Group (UNH) stood at $278.58, denoting a -4.76% move from the preceding trading day.
Company shares have tumbled since December, when UnitedHealthcare CEO Brian Thompson was fatally shot in midtown Manhattan.
UNH braces for a 27% earnings drop in Q2 as soaring medical costs, margin pressure and investor jitters weigh on performance.
Only the tech-heavy (AI-trade-heavy) Nasdaq is in the green at this hour.
UnitedHealth Group's stock fell Thursday after the company confirmed government criminal and civil investigations into its Medicare practices but stressed that it doesn't expect to be charged with any wrongdoing.
Evaluate the expected performance of UnitedHealth (UNH) for the quarter ended June 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Zacks.com users have recently been watching UnitedHealth (UNH) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.